ArticleBlood advances2019
Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission.
Open access · goldAbstract readComparative Study
In one paragraph
Article in Blood advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed, 2 pooled it
11.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 2 syntheses or guidelines pooled it, 127 citations in OpenAlex.
- American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation.Blood advances · 2021Guideline
- Pooled it
- A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation.Blood advances · 2021Trial
- Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults.Blood advances · 2020Trial
- ATIR101 administered after T-cell-depleted haploidentical HSCT reduces NRM and improves overall survival in acute leukemia.Leukemia · 2020Trial
- Haploidentical versus HLA-matched sibling transplantation for refractory acute leukemia undergoing sequential intensified conditioning followed by DLI: an analysis from two prospective data.Journal of hematology & oncology · 2020Trial
- FLT3-Mutated AML: Transplanting with Precision in the Targeted Era.Current hematologic malignancy reports · 2026Review
- Outcomes After Matched Sibling Donor Versus Haploidentical Hematopoietic Stem Cell Transplantation With Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis.Transplantation and cellular therapy · 2026Article
- Haploidentical transplantation with post-transplant cyclophosphamide is not inferior to 9/10-MUD transplantation with ATG in patients with myeloid malignancies.Bone marrow transplantation · 2026Article
- Article
- Article
- Incidence, Risk Factors, and Outcomes of Viral Reactivations in Alternative Donor Hematopoietic Stem Cell Transplants.Blood cell therapy · 2025Article
- Article
- Haploidentical Hematopoietic Stem Cell Transplantation for AML Patients with Persistent Molecular MRD.Current medical science · 2025Article
- Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and Management.American journal of hematology · 2025Review
- Pretransplantation risk factors for positive MRD after allogeneic stem cell transplantation in AML patients: a prospective study.Bone marrow transplantation · 2025Article
- Article
- Outcomes of haploidentical transplants with PT-CY vs 10/10 MUD transplants with ATG in Germany.Blood advances · 2024Article
- Allogeneic hematopoietic cell transplantation from alternative donors in acute myeloid leukemia.Annals of hematology · 2024Review
- ASTCT Consensus Recommendations on Testing and Treatment of Patients with Donor-specific Anti-HLA Antibodies.Transplantation and cellular therapy · 2024Review
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
70 authors at 20 institutions in 13 countries.
Armin RashidiDepartment of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN.ORCID 0000-0002-9384-272X
Mehdi HamadaniCenter for International Blood and Marrow Transplant Research, Department of Medicine, and.ORCID 0000-0001-5372-510X
Mei-Jie ZhangCenter for International Blood and Marrow Transplant Research, Department of Medicine, and.
Hai-Lin WangCenter for International Blood and Marrow Transplant Research, Department of Medicine, and.
Hisham Abdel-AzimDivision of Hematology, Oncology and Blood & Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA.
Mahmoud AljurfDepartment of Oncology, King Faisal Specialist Hospital Center & Research, Riyadh, Saudi Arabia.
Amer AssalNYPH/Columbia University Medical Center, New York, NY.ORCID 0000-0003-4707-9265
Ashish BajelRoyal Melbourne Hospital City Campus, Parkville, VIC, Australia.
Asad BasheyThe Blood and Marrow Transplant Program, Northside Hospital, Atlanta, GA.
Minoo BattiwallaHematology Branch, Sarah Cannon BMT Program, Nashville, TN.
Amer M BeitinjanehUniversity of Miami, Miami, FL.
Nelli BejanyanDepartment of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Minneapolis, MN.
Vijaya Raj BhattThe Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE.
Javier Bolaños-MeadeThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.
Michael ByrneVanderbilt University Medical Center, Nashville, TN.
Jean-Yves CahnDepartment of Hematology, CHU Grenoble Alpes, Grenoble, France.
Mitchell CairoDivision of Pediatric Hematology, Oncology and Stem Cell Transplantation, Department of Pediatrics, New York Medical College, Valhalla, NY.
Stefan CiureaMD Anderson Cancer Center, Houston, TX.
Edward CopelanLevine Cancer Institute, Atrium Health, Carolinas HealthCare System, Charlotte, NC.
Corey CutlerDana-Farber Cancer Institute, Boston, MA.
Andrew DalyTom Baker Cancer Center, Calgary, AB, Canada.
Miguel-Angel DiazDepartment of Hematology/Oncology, Hospital Infantil Universitario Nino Jesus, Madrid, Spain.
Nosha FarhadfarDivision of Hematology/Oncology, University of Florida College of Medicine, Gainesville, FL.
Robert P GaleHematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, United Kingdom.ORCID 0000-0002-9156-1676
Siddhartha GangulyUniversity of Kansas, Westwood, KS.
Michael R GrunwaldLevine Cancer Institute, Atrium Health, Carolinas HealthCare System, Charlotte, NC.
Theresa HahnDepartment of Medicine, Roswell Park Cancer Institute, Buffalo, NY.
Shahrukh HashmiDepartment of Oncology, King Faisal Specialist Hospital Center & Research, Riyadh, Saudi Arabia.ORCID 0000-0002-8914-7927
Gerhard C HildebrandtMarkey Cancer Center, University of Kentucky, Lexington, KY.ORCID 0000-0003-0478-3340
H Kent HollandThe Blood and Marrow Transplant Program, Northside Hospital, Atlanta, GA.
Nasheed HossainLoyola University Chicago Stritch School of Medicine, Maywood IL.
Christopher G KanakryExperimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Mohamed A Kharfan-DabajaDivision of Hematology-Oncology, Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL.
Nandita KheraDepartment of Hematology/Oncology, Mayo Clinic, Phoenix, AZ.
Yener KocMedical Park Hospital, Antalya, Turkey.
Hillard M LazarusCase Western Reserve University, Cleveland, OH.
Jong-Wook LeeDivision of Hematology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea.
Johan MaertensUniversity Hospital Gasthuisberg, Leuven, Belgium.
Rodrigo MartinoDivison of Clinical Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Joseph McGuirkUniversity of Kansas, Westwood, KS.ORCID 0000-0002-0539-4796
Reinhold MunkerSection of Hematology/Oncology, Department of Internal Medicine, Louisiana State University Health Shreveport, Shreveport, LA.
Hemant S MurthyDivision of Hematology/Oncology, University of Florida College of Medicine, Gainesville, FL.ORCID 0000-0003-4534-4248
Ryotaro NakamuraDepartment of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA.
Sunita NathanRush University Medical Center, Chicago, IL.
Taiga NishihoriDepartment of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.ORCID 0000-0002-2621-7924
Neil PalmisianoThomas Jefferson University Hospital, Philadelphia, PA.
Sagar PatelBlood and Marrow Transplant Program, Cleveland Clinic Foundation, Cleveland, OH.ORCID 0000-0001-9949-3615
Joseph PidalaH. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
Rebecca OlinUniversity of California San Francisco Medical Center, San Francisco, CA.
Richard F OlssonDepartment of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0001-5970-2128
Betul OranDivision of Cancer Medicine, Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX.
Olov RingdenTranslational Cell Therapy Research, Clintec, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0002-6092-1536
David RizzieriDivision of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC.
Jacob RoweDepartment of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel.
Mary Lynn SavoieTom Baker Cancer Center, Calgary, AB, Canada.ORCID 0000-0003-0301-5139
Kirk R SchultzDepartment of Pediatric Hematology, Oncology and Bone Marrow Transplant, British Columbia Children's Hospital, The University of British Columbia, Vancouver, BC, Canada.
Sachiko SeoDepartment of Hematology and Oncology, Dokkyo Medical University. Mibu, Japan.
Brian C ShafferMemorial Sloan Kettering Cancer Center, New York, NY.
Anurag SinghUniversity of Kansas, Westwood, KS.
Melhem SolhThe Blood and Marrow Transplant Program, Northside Hospital, Atlanta, GA.
Keith Stockerl-GoldsteinBarnes Jewish Hospital, St. Louis, MO.
Leo F VerdonckDepartment of Hematology/Oncology, Isala Clinic, Zwolle, The Netherlands.
John WagnerThomas Jefferson University Hospital, Philadelphia, PA.ORCID 0000-0001-8468-6764
Edmund K WallerDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA.ORCID 0000-0003-0816-6729
Marcos De LimaDepartment of Medicine, Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, OH.
Brenda M SandmaierDivision of Medical Oncology, University of Washington and Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.ORCID 0000-0002-9767-9739
Mark LitzowDivision of Hematology and Transplant Center, Mayo Clinic Rochester, Rochester, MN; and.ORCID 0000-0002-9816-6302
Dan WeisdorfDivision of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota Medical Center, Minneapolis, MN.ORCID 0000-0001-8078-8579
Rizwan RomeeDana-Farber Cancer Institute, Boston, MA.
Wael SaberCenter for International Blood and Marrow Transplant Research, Department of Medicine, and.
Moffitt Cancer Center · USNorthside Hospital · USUniversity of Kansas · USCarolinas Healthcare System · USDana-Farber Cancer Institute · USKing Faisal Specialist Hospital & Research Centre · SAThe University of Texas MD Anderson Cancer Center · USThomas Jefferson University Hospital · USUniversity of Florida · USAntalya IVF · TRBarnes-Jewish Hospital · USCase Western Reserve University · USCentre Hospitalier Universitaire de Grenoble · FRCity of Hope · USCleveland Clinic · USColumbia University Irving Medical Center · USDokkyo Medical University · JPDuke University · USEmory University · USHospital de Sant Pau · ES
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MData Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2MEasy-to-read Informed Consent for HCT Clinical TrialsU10HL069294 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI HOROWITZ, MARY MARESCA · 2011 to 2016
$43.8MDeciphering the efficacy of posttransplant cyclophosphamide in haplo transplantZIABC011659 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KANAKRY, CHRISTOPHER · 2015 to 2025
$18.5MNCI NIH HHS P30 CA008748NCI NIH HHS U24 CA076518NHLBI NIH HHS U10 HL069294
Abstract
HLA-haploidentical hematopoietic cell transplantation (Haplo-HCT) using posttransplantation cyclophosphamide (PT-Cy) has improved donor availability. However, a matched sibling donor (MSD) is still considered the optimal donor. Using the Center for International Blood and Marrow Transplant Research database, we compared outcomes after Haplo-HCT vs MSD in patients with acute myeloid leukemia (AML) in first complete remission (CR1). Data from 1205 adult CR1 AML patients (2008-2015) were analyzed. A total of 336 patients underwent PT-Cy-based Haplo-HCT and 869 underwent MSD using calcineurin inhibitor-based graft-versus-host disease (GVHD) prophylaxis. The Haplo-HCT group included more reduced-intensity conditioning (65% vs 30%) and bone marrow grafts (62% vs 7%), consistent with current practice. In multivariable analysis, Haplo-HCT and MSD groups were not different with regard to overall survival (
Indexed as
AdolescentAdultAgedBlood DonorsBone Marrow TransplantationCalcineurin InhibitorsChronic DiseaseCyclophosphamideDisease-Free SurvivalFemaleGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansImmunosuppressive AgentsIncidenceLeukemia, Myeloid, AcuteCalcineurin InhibitorsCyclophosphamideImmunosuppressive Agents
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.